Overview

A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma

Status:
Not yet recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This is a single centre, 2-cell, single blinded full-face (products applied at lesional sites) study to evaluate changes in melasma through a cosmetic facial serum formulation and marketed 2% Hydroquinone product

Phase:

N/A

Details

Lead Sponsor:

Unilever R&D

Collaborator:

Shanghai Skin Disease and Venereal Disease Hospital

Treatments:

Hydroquinone